Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer

HuangC-E., C. H. Lu, P. T. Chen, C. H.H. Chan, W. C. Chen, W. H. Wang, J. Y. Wu, F. C. Kuan, K. D. Lee, C. C. Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

What is known and Objective: The beneficial effects of docetaxel plus cisplatin-based induction chemotherapy for patients with unresectable, advanced head and neck cancer (HNC) have been documented in Western countries. However, the efficacy of such treatment has not been confirmed in Asian patients. We aimed to determine whether incorporation of dose-modified docetaxel into a cisplatin-based induction regimen would be both effective and tolerable in our Asian population of patients. Methods: Thirty-six patients with stage III or IV HNC who had undergone cisplatin-based induction chemotherapy were included in the current analysis. Fifty-three percentage of the patients had received induction chemotherapy with bolus cisplatin and continuous 5-fluorouracil (PF group), while the remaining 47% had additionally received dose-modified docetaxel (TPF group). We assessed the relative impact of the two treatments on clinical outcomes and treatment-related toxicities. Results and Discussion: The disease control rate was higher in the TPF group (92.9% vs. 76.5%), although the difference did not reach statistical significance (P = 0.217). Addition of docetaxel increased the median progression-free survival to 435 days, which was 2.3 times longer than that (188 days) of patients not receiving docetaxel (P = 0.019). Non-haematological toxicity profile was similar and acceptable in both treatment groups. Higher incidence of grade 3/4 neutropenia and more episodes of neutropenic fever-related hospitalization occurred in the docetaxel-treated patients, but most of them were managed uneventfully. What is new and conclusion: Addition of dose-modified docetaxel to cisplatin-based induction chemotherapy was both efficacious and generally safe. Docetaxel addition significantly prolonged progression-free survival and had an acceptable safety profile in our Asian population of patients with locoregionally advanced HNC.

Original languageEnglish
Pages (from-to)342-347
Number of pages6
JournalJournal of Clinical Pharmacy and Therapeutics
Volume37
Issue number3
DOIs
Publication statusPublished - Jun 2012
Externally publishedYes

Fingerprint

docetaxel
Induction Chemotherapy
Head and Neck Neoplasms
Cisplatin
Safety
Disease-Free Survival
Neutropenia
Fluorouracil
Population

Keywords

  • docetaxel
  • dose-modified
  • head and neck cancer
  • induction chemotherapy
  • progression-free survival

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. / HuangC-E.; Lu, C. H.; Chen, P. T.; Chan, C. H.H.; Chen, W. C.; Wang, W. H.; Wu, J. Y.; Kuan, F. C.; Lee, K. D.; Chen, C. C.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 37, No. 3, 06.2012, p. 342-347.

Research output: Contribution to journalArticle

HuangC-E. ; Lu, C. H. ; Chen, P. T. ; Chan, C. H.H. ; Chen, W. C. ; Wang, W. H. ; Wu, J. Y. ; Kuan, F. C. ; Lee, K. D. ; Chen, C. C. / Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. In: Journal of Clinical Pharmacy and Therapeutics. 2012 ; Vol. 37, No. 3. pp. 342-347.
@article{24edc69d8af240c788a788b9a3a4668b,
title = "Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer",
abstract = "What is known and Objective: The beneficial effects of docetaxel plus cisplatin-based induction chemotherapy for patients with unresectable, advanced head and neck cancer (HNC) have been documented in Western countries. However, the efficacy of such treatment has not been confirmed in Asian patients. We aimed to determine whether incorporation of dose-modified docetaxel into a cisplatin-based induction regimen would be both effective and tolerable in our Asian population of patients. Methods: Thirty-six patients with stage III or IV HNC who had undergone cisplatin-based induction chemotherapy were included in the current analysis. Fifty-three percentage of the patients had received induction chemotherapy with bolus cisplatin and continuous 5-fluorouracil (PF group), while the remaining 47{\%} had additionally received dose-modified docetaxel (TPF group). We assessed the relative impact of the two treatments on clinical outcomes and treatment-related toxicities. Results and Discussion: The disease control rate was higher in the TPF group (92.9{\%} vs. 76.5{\%}), although the difference did not reach statistical significance (P = 0.217). Addition of docetaxel increased the median progression-free survival to 435 days, which was 2.3 times longer than that (188 days) of patients not receiving docetaxel (P = 0.019). Non-haematological toxicity profile was similar and acceptable in both treatment groups. Higher incidence of grade 3/4 neutropenia and more episodes of neutropenic fever-related hospitalization occurred in the docetaxel-treated patients, but most of them were managed uneventfully. What is new and conclusion: Addition of dose-modified docetaxel to cisplatin-based induction chemotherapy was both efficacious and generally safe. Docetaxel addition significantly prolonged progression-free survival and had an acceptable safety profile in our Asian population of patients with locoregionally advanced HNC.",
keywords = "docetaxel, dose-modified, head and neck cancer, induction chemotherapy, progression-free survival",
author = "HuangC-E. and Lu, {C. H.} and Chen, {P. T.} and Chan, {C. H.H.} and Chen, {W. C.} and Wang, {W. H.} and Wu, {J. Y.} and Kuan, {F. C.} and Lee, {K. D.} and Chen, {C. C.}",
year = "2012",
month = "6",
doi = "10.1111/j.1365-2710.2011.01306.x",
language = "English",
volume = "37",
pages = "342--347",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer

AU - HuangC-E.,

AU - Lu, C. H.

AU - Chen, P. T.

AU - Chan, C. H.H.

AU - Chen, W. C.

AU - Wang, W. H.

AU - Wu, J. Y.

AU - Kuan, F. C.

AU - Lee, K. D.

AU - Chen, C. C.

PY - 2012/6

Y1 - 2012/6

N2 - What is known and Objective: The beneficial effects of docetaxel plus cisplatin-based induction chemotherapy for patients with unresectable, advanced head and neck cancer (HNC) have been documented in Western countries. However, the efficacy of such treatment has not been confirmed in Asian patients. We aimed to determine whether incorporation of dose-modified docetaxel into a cisplatin-based induction regimen would be both effective and tolerable in our Asian population of patients. Methods: Thirty-six patients with stage III or IV HNC who had undergone cisplatin-based induction chemotherapy were included in the current analysis. Fifty-three percentage of the patients had received induction chemotherapy with bolus cisplatin and continuous 5-fluorouracil (PF group), while the remaining 47% had additionally received dose-modified docetaxel (TPF group). We assessed the relative impact of the two treatments on clinical outcomes and treatment-related toxicities. Results and Discussion: The disease control rate was higher in the TPF group (92.9% vs. 76.5%), although the difference did not reach statistical significance (P = 0.217). Addition of docetaxel increased the median progression-free survival to 435 days, which was 2.3 times longer than that (188 days) of patients not receiving docetaxel (P = 0.019). Non-haematological toxicity profile was similar and acceptable in both treatment groups. Higher incidence of grade 3/4 neutropenia and more episodes of neutropenic fever-related hospitalization occurred in the docetaxel-treated patients, but most of them were managed uneventfully. What is new and conclusion: Addition of dose-modified docetaxel to cisplatin-based induction chemotherapy was both efficacious and generally safe. Docetaxel addition significantly prolonged progression-free survival and had an acceptable safety profile in our Asian population of patients with locoregionally advanced HNC.

AB - What is known and Objective: The beneficial effects of docetaxel plus cisplatin-based induction chemotherapy for patients with unresectable, advanced head and neck cancer (HNC) have been documented in Western countries. However, the efficacy of such treatment has not been confirmed in Asian patients. We aimed to determine whether incorporation of dose-modified docetaxel into a cisplatin-based induction regimen would be both effective and tolerable in our Asian population of patients. Methods: Thirty-six patients with stage III or IV HNC who had undergone cisplatin-based induction chemotherapy were included in the current analysis. Fifty-three percentage of the patients had received induction chemotherapy with bolus cisplatin and continuous 5-fluorouracil (PF group), while the remaining 47% had additionally received dose-modified docetaxel (TPF group). We assessed the relative impact of the two treatments on clinical outcomes and treatment-related toxicities. Results and Discussion: The disease control rate was higher in the TPF group (92.9% vs. 76.5%), although the difference did not reach statistical significance (P = 0.217). Addition of docetaxel increased the median progression-free survival to 435 days, which was 2.3 times longer than that (188 days) of patients not receiving docetaxel (P = 0.019). Non-haematological toxicity profile was similar and acceptable in both treatment groups. Higher incidence of grade 3/4 neutropenia and more episodes of neutropenic fever-related hospitalization occurred in the docetaxel-treated patients, but most of them were managed uneventfully. What is new and conclusion: Addition of dose-modified docetaxel to cisplatin-based induction chemotherapy was both efficacious and generally safe. Docetaxel addition significantly prolonged progression-free survival and had an acceptable safety profile in our Asian population of patients with locoregionally advanced HNC.

KW - docetaxel

KW - dose-modified

KW - head and neck cancer

KW - induction chemotherapy

KW - progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=84861332844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861332844&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.2011.01306.x

DO - 10.1111/j.1365-2710.2011.01306.x

M3 - Article

VL - 37

SP - 342

EP - 347

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 3

ER -